Equities analysts predict that Xenon Pharmaceuticals Inc. (NASDAQ:XENE) will report $3.70 million in sales for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for Xenon Pharmaceuticals’ earnings. The highest sales estimate is $5.50 million and the lowest is $2.50 million. Xenon Pharmaceuticals posted sales of $7.08 million during the same quarter last year, which suggests a negative year-over-year growth rate of 47.7%. The business is expected to announce its next quarterly earnings report on Thursday, May 20th.
On average, analysts expect that Xenon Pharmaceuticals will report full year sales of $20.59 million for the current fiscal year, with estimates ranging from $11.30 million to $36.50 million. For the next year, analysts expect that the company will post sales of $29.76 million, with estimates ranging from $6.70 million to $56.60 million. Zacks Investment Research’s sales averages are a mean average based on a survey of sell-side research firms that cover Xenon Pharmaceuticals.
Xenon Pharmaceuticals (NASDAQ:XENE) last released its quarterly earnings results on Monday, March 1st. The biopharmaceutical company reported ($0.34) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.40) by $0.06. The company had revenue of $5.15 million during the quarter, compared to analysts’ expectations of $3.50 million. Xenon Pharmaceuticals had a negative net margin of 102.25% and a negative return on equity of 21.76%.
Hedge funds and other institutional investors have recently bought and sold shares of the business. Credit Suisse AG raised its position in Xenon Pharmaceuticals by 35.0% during the fourth quarter. Credit Suisse AG now owns 18,478 shares of the biopharmaceutical company’s stock worth $283,000 after acquiring an additional 4,793 shares in the last quarter. DekaBank Deutsche Girozentrale bought a new stake in Xenon Pharmaceuticals during the fourth quarter worth $157,000. Raymond James Financial Services Advisors Inc. bought a new stake in Xenon Pharmaceuticals during the fourth quarter worth $158,000. Accel Wealth Management bought a new stake in Xenon Pharmaceuticals during the fourth quarter worth $138,000. Finally, Bank of New York Mellon Corp raised its position in Xenon Pharmaceuticals by 27.1% during the fourth quarter. Bank of New York Mellon Corp now owns 949,238 shares of the biopharmaceutical company’s stock worth $14,599,000 after acquiring an additional 202,435 shares in the last quarter. 79.90% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Xenon Pharmaceuticals stock traded down $0.28 on Tuesday, hitting $18.35. The company had a trading volume of 93,042 shares, compared to its average volume of 183,065. The firm has a market capitalization of $751.67 million, a P/E ratio of -18.92 and a beta of 1.20. Xenon Pharmaceuticals has a twelve month low of $9.32 and a twelve month high of $21.94. The stock has a 50-day moving average of $18.44 and a 200-day moving average of $15.19.
About Xenon Pharmaceuticals
Xenon Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN496, A Kv7 potassium channel modulator that is Phase III clinical trials for the treatment of KCNQ2 epilepsy encephalopathy; and XEN1101, A Kv7 potassium channel modulator, which is in Phase II clinical trial for the treatment of epilepsy and other neurological disorders.
Read More: CAC 40 Index
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.